New Drug: Tekturna (Aliskiren)

Tekturna (Aliskiren) was approved in March 2007 as the first renin inhibitor for the treatment of hypertension. It maybe used as monotherapy or adjunct therapy with other antihypertensives. Tekturna is manufactured by Novartis. The most common adverse reaction is dose-related diarrhea. Tekturna is supplied as 150- and 300-mg tablets. Tekturna is FDA pregnancy category C in the first trimester and category D in the second and third trimesters. treament with this agent should be discontinued as soon as possible in pregannat patients.
Go to http://www.tekturna.com